Next Investors logo grey

Digestive health supplement lifts Immuron’s sales


Published 15-APR-2019 13:03 P.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Immuron Limited (ASX:IMC | NASDAQ:IMRN) today announced that sales for its commercially available products, including Travelan®, surged by 66% in the third quarter.

Immuron is an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, including Travelan®, its over-the-counter gastrointestinal and digestive health supplement.

Worldwide product sales reached $616,000 in the quarter ending March 31, up from 371,000 in Q3 2018. While sales for the year to date hit $1.7 million, up 23% from this time a year ago.

In Australia, Travelan® sales rocketed to A$332,000 in Q3 FY19, representing a 73% increase over Q3 FY18 (A$192,000) demonstrating that efforts to raise consumer awareness of the brand through expanded co-operative Marketing initiatives with major Pharmacy banners have impacted positively on sales.

Sales for the year to March 31 of Travelan® in Australia exceeded the A$1 million mark and are 18% higher than the same time last year.

In the US, Travelan® sales surged ahead growing 60% YoY to A$266,000 for Q3 2019 as the partnership with USA’s largest travel medicine network, Passport Health continues.

Sales of Travelan® on the Amazon Platform are also steadily increasing. YTD March 31 US Sales (A$635,000) are sitting 27% higher than the same time last year.

Dr Gary S. Jacob, CEO of Immuron, said of the results, “Our concerted focus on expanding sales growth of Travelan® within existing markets, coupled with our re-entry into Canada puts us in a strong position for continued growth.

“We will continue to work towards expanded sales growth, with particular emphasis on building the market for Travelan® in North America.”

Today’s announcement follows news last week that IMC plans to pursue clinical development of IMM-124E, its bovine polyclonal antibody drug candidate to prevent travelers’ diarrhea, through a formal FDA registration pathway.

It also comes after the company's Chemist Warehouse Ad went live on April 12 and wil run through to April 18:

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.